3 Horrendous Healthcare Stocks This Week   4-4-14
Upcoming SlideShare
Loading in...5
×
 

3 Horrendous Healthcare Stocks This Week 4-4-14

on

  • 3,613 views

3 of this week's most horrendous health-care stocks.

3 of this week's most horrendous health-care stocks.

Statistics

Views

Total Views
3,613
Views on SlideShare
616
Embed Views
2,997

Actions

Likes
0
Downloads
1
Comments
0

7 Embeds 2,997

http://www.fool.com 2938
http://m.fool.com 25
http://www.barchart.com 25
http://translate.googleusercontent.com 4
http://cms.fool.com 2
http://barchartjson.websol.barchart.com 2
http://www.mysanantonio.com 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

3 Horrendous Healthcare Stocks This Week   4-4-14 3 Horrendous Healthcare Stocks This Week 4-4-14 Presentation Transcript

  • 3 Horrendous Health-Care Stocks This Week
  • Our favorite holiday at The Motley Fool, April Fools’ Day, has come and gone. The joke is still on shareholders for some health-care stocks, though. Here are this week’s horrendous losers.
  • The biotech’s shares plunged over 30% for the week. Halozyme Therapeutics (Nasdaq: HALO) Source: Yahoo! Finance
  • • Halozyme paused its mid-stage study of PEGPH20 because of safety concerns. • Patients taking the pancreatic- cancer drug may be more likely to experience blocked blood vessels. • Halozyme is reviewing the clinical data to determine its next steps. Why Halozyme’s shares got hammered
  • Shares of the pharmaceutical company dropped 26% this week. Dicerna Pharmaceuticals (Nasdaq: DRNA) Source: Yahoo! Finance
  • • There was no big news this week for Dicerna, aside from naming a new chief medical officer. • The company launched its IPO in January and saw shares skyrocket on the first day of trading. • Dicerna’s stock has been on a steady downward trajectory since March 21 -- probably at least partially because of the larger biotech sell-off. Why Dicerna’s stock got diced
  • The stock of the biotech fell nearly 20% this week. Momenta Pharmaceuticals (Nasdaq: MNTA) Source: Yahoo! Finance
  • • Good news for Teva Pharmaceuticals (NYSE: TEVA) meant bad news for Momenta. • The U.S. Supreme Court agreed to hear an appeal of a lower-court decision that allowed generic versions of Teva’s multiple sclerosis drug, Copaxone, to be marketed starting in May. • Momenta hoped to be able to launch its generic version of Copaxone soon but will now be delayed in doing so. Why Momenta lost its mojo
  • • Halozyme could come back, but not until the cloud hanging over PEGPH20 goes away. • Momenta might take a while to come back -- the Supreme Court won’t even hear Teva’s appeal until October at the earliest. • Dicerna’s RNAi delivery system seems promising. • While the stock could drop some more in the near term, Dicerna has a good shot at seeing a nice rebound this year. Best shot at bouncing back?
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!